Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991;10:295–297.
43.
Rustin GJS, van der Burg MEL, Berek JS. Tumor markers. Ann Oncol 1993;4:S71–S77.
44.
Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurements and ultrasonography. BMJ 1993;306:1030–1034.
45.
Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355–1358.
46.
Einhorn N, Sjovall K, Knapp RC, et al. A prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14–18.
47.
Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA125, CA15–3, and TAG 72.3. Obstet Gynecol 1992;80:396– 399.
48.
Berek JS, Bast RC Jr. Ovarian cancer screening: the use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995;76:2092–2096.
49.
Skates SJ, Xu FJ, Yu YH, et al. Towards an optimal algorithm for ovarian cancer screening with longitudinal tumour markers. Cancer 1995;76:2004–2010.
50.
Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207– 1210.
51.
Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21(Suppl):206–210.
52.
Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–577.
53.
Zhang Z, Bast RC Jr, Fung E, et al. A panel of serum biomarkers identified through proteomic profiling for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882–5890.
54.
American College of Obstetricians and Gynecologists. Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion 117. Washington, DC: ACOG, 1992.
55.
Woodward ER, Sleightholme HV, Considine AM, et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007;114:1500–1509.
56.